A Complex Systems Approach to Evaluate HIV Prevention in Metropolitan Areas: Preliminary Implications for Combination Intervention Strategies

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Marshall, Brandon D L ^a,b   Paczkowski, Magdalena M ^a   Seemann, Lars ^c   Tempalski, Barbara ^d   Pouget, Enrique R ^d   Galea, Sandro ^a   Friedman, Samuel R ^d  

^a Department of Medicine   (United States)

^b BROWN UNIVERSITY   (United States)

^c University of Houston   (United States)

^d NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGENT BASED MODEL; ARTICLE; CONCEPTUAL FRAMEWORK; DRUG DEPENDENCE TREATMENT; HEALTH PROGRAM; HIGH RISK BEHAVIOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MALE HOMOSEXUAL; MATHEMATICAL MODEL; PREVALENCE; RISK ASSESSMENT; STOCHASTIC MODEL; SUBSTANCE ABUSE; UNSAFE SEX; URBAN AREA; VIRUS TRANSMISSION;

CITIES; COMMUNICABLE DISEASE CONTROL; DRUG USERS; FEMALE; HIV INFECTIONS; HOMOSEXUALITY; HUMANS; INJECTIONS; MALE; MODELS, STATISTICAL; RISK; RISK-TAKING;

EID: 84866392789     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044833     Document Type: Article

References (179)

1. Joint United Nations Programme on HIV/AIDS (2010) Global Report: UNAIDS Report on the Global AIDS Epidemic 2010. Geneva, Switzerland: UNAIDS.
2. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
3. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599.
4. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.
5. Kippax SC, Holt M, Friedman SR, (2011) Bridging the social and the biomedical: engaging the social and political sciences in HIV research. J Int AIDS Soc 14: S1.
6. MacQueen KM, (2011) Framing the social in biomedical HIV prevention trials: a 20-year retrospective. J Int AIDS Soc 14: S3.
7. Padian NS, McCoy SI, Karim SS, Hasen N, Kim J, et al. (2011) HIV prevention transformed: the new prevention research agenda. Lancet 378: 269-278.
8. Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN, (2011) Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep 8: 62-72.
9. Piot P, Bartos M, Larson H, Zewdie D, Mane P, (2008) Coming to terms with complexity: a call to action for HIV prevention. Lancet 372: 845-859.
10. Coates TJ, Richter L, Caceres C, (2008) Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 372: 669-684.
11. Joint United Nations Programme on HIV/AIDS (2009) Joint action for results: UNAIDS outcome framework, 2009-2011. Geneva, Switzerland: UNAIDS.
12. Halperin DT, (2009) Combination HIV prevention must be based on evidence. Lancet 373: 544-545.
13. Merson M, Padian N, Coates TJ, Gupta GR, Bertozzi SM, et al. (2008) Combination HIV prevention. Lancet 372: 1805-1806.
14. Hankins CA, de Zalduondo BO, (2010) Combination prevention: a deeper understanding of effective HIV prevention. AIDS 24: S70-S80.
15. Galea S, Hall C, Kaplan GA, (2009) Social epidemiology and complex system dynamic modelling as applied to health behaviour and drug use research. Int J Drug Policy 20: 209-216.
16. DeGruttola V, Smith DM, Little SJ, Miller V, (2010) Developing and evaluating comprehensive HIV infection control strategies: issues and challenges. Clin Infect Dis 50: S102-107.
17. Rotheram-Borus MJ, Swendeman D, Chovnick G, (2009) The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annu Rev Clin Psychol 5: 143-167.
18. Auchincloss AH, Diez Roux AV, (2008) A new tool for epidemiology: the usefulness of dynamic-agent models in understanding place effects on health. Am J Epidemiol 168: 1-8.
19. Friedman SR, Rossi D, Braine N, (2009) Theorizing "Big Events" as a potential risk environment for drug use, drug-related harm and HIV epidemic outbreaks. Int J Drug Policy 20: 283-291.
20. Frohlich KL, Potvin L, (2008) Transcending the known in public health practice: the inequality paradox: the population approach and vulnerable populations. Am J Public Health 98: 216-221.
21. Miller JH, Page SE (2007) Complex Adaptive Systems: An Introduction to Computational Models of Social Life. Princeton, NJ: Princeton University Press.
22. Galea S, Riddle M, Kaplan GA, (2010) Causal thinking and complex system approaches in epidemiology. Int J Epidemiol 39: 97-106.
23. Sterman JD, (1994) Learning in and About Complex-Systems. Syst Dynam Rev 10: 291-330.
24. Foster J, (2005) From simplistic to complex systems in economics. Cambridge J Econ 29: 873-892.
25. Epstein JM (2006) Generative Social Science: Studies in Agent-Based Computational Modeling. Princeton, NJ: Princeton University Press.
26. Sterman JD, (2006) Learning from evidence in a complex world. Am J Public Health 96: 505-514.
27. Aral SO, Leichliter JS, Blanchard JF, (2010) Overview: the role of emergent properties of complex systems in the epidemiology and prevention of sexually transmitted infections including HIV infection. Sex Transm Infect 86: iii1-iii3.
28. Maglio PP, Mabry PL, (2011) Agent-based models and systems science approaches to public health. Am J Prev Med 40: 392-394.
29. Bonabeau E, (2002) Agent-based modeling: methods and techniques for simulating human systems. Proc Natl Acad Sci U S A 99: 7280-7287.
30. Moore D, Dray A, Green R, Hudson SL, Jenkinson R, et al. (2009) Extending drug ethno-epidemiology using agent-based modelling. Addiction 104: 1991-1997.
31. Gorman DM, Mezic J, Mezic I, Gruenewald PJ, (2006) Agent-based modeling of drinking behavior: a preliminary model and potential applications to theory and practice. Am J Public Health 96: 2055-2060.
32. Bagni R, Berchi R, Cariello P, (2002) A comparison of simulation models applied to epidemics. JASSS- J Artif Soc S 5: 3.
33. Perez L, Dragicevic S, (2009) An agent-based approach for modeling dynamics of contagious disease spread. Int J Health Geogr 8: 50.
34. Zanette DH, Risau-Gusman S, (2008) Infection spreading in a population with evolving contacts. J Biol Phys 34: 135-148.
35. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, et al. (2008) Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372: 1733-1745.
36. Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Beatrice S, et al. (2005) HIV incidence among injection drug users in New York City, 1990 to 2002: Use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public Health 95: 1439-1444.
37. Kerr T, Small W, Buchner C, Zhang R, Li K, et al. (2010) Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. Am J Public Health 100: 1449-1453.
38. Des Jarlais DC, Arasteh K, Perlis T, Hagan H, Abdul-Quader A, et al. (2007) Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City. AIDS 21: 231-235.
39. DeBeck K, Kerr T, Li K, Fischer B, Buxton J, et al. (2009) Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. CMAJ 181: 585-589.
40. Strathdee SA, Sherman SG, (2003) The role of sexual transmission of HIV infection among injection and non-injection drug users. J Urban Health 80: iii7-iii14.
41. Des Jarlais DC, Semaan S, (2008) HIV prevention for injecting drug users: the first 25 years and counting. Psychosom Med 70: 606-611.
42. World Health Organization (2009) WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. Geneva, Switzerland: WHO, UNODC, UNAIDS.
43. Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M, (2007) Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 102: 1454-1462.
44. Des Jarlais DC, Arasteh K, McKnight C, Hagan H, Perlman DC, et al. (2010) HIV infection during limited versus combined HIV prevention programs for IDUs in New York City: the importance of transmission behaviors. Drug Alcohol Depend 109: 154-160.
45. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, et al. (2010) Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 376: 285-301.
46. Fuller CM, Vlahov D, Ompad DC, Shah N, Arria A, et al. (2002) High-risk behaviors associated with transition from illicit non-injection to injection drug use among adolescent and young adult drug users: A case-control study. Drug Alcohol Depend 66: 189-198.
47. Friedman SR, Curtis R, Neaigus A, Jose B, Des Jarlais DC (2010) Social Networks, Drug Injectors' Lives, and HIV/AIDS. New York, NY: Kluwer Academic, Inc.
48. Halkitis PN, Mukherjee PP, Palamar JJ, (2007) Multi-level modeling to explain methamphetamine use among gay and bisexual men. Addiction 102: 76-83.
49. Galea S, Nandi A, Coffin PO, Tracy M, Markham Piper T, et al. (2006) Heroin and cocaine dependence and the risk of accidental non-fatal drug overdose. J Addict Dis 25: 79-87.
50. Des Jarlais DC, Arasteh K, Friedman SR, (2011) HIV among drug users at Beth Israel Medical Center, New York City, the first 25 years. Subst Use Misuse 46: 131-139.
51. Institute of Medicine (2007) Preventing HIV Infection among Injecting Drug Users in High Risk Countries: An Assessment of the Evidence. Washington, DC: National Academy of Sciences.
52. Gibson DR, Flynn NM, Perales D, (2001) Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 15: 1329-1341.
53. Hagan H, McGough JP, Thiede H, Hopkins S, Duchin J, et al. (2000) Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. J Subst Abuse Treat 19: 247-252.
54. Heimer R, Grau LE, Curtin E, Khoshnood K, Singer M, (2007) Assessment of HIV testing of urban injection drug users: implications for expansion of HIV testing and prevention efforts. Am J Public Health 97: 110-116.
55. Heimer R, (1998) Can syringe exchange serve as a conduit to substance abuse treatment? J Subst Abuse Treat 15: 183-191.
56. Strathdee SA, Celentano DD, Shah N, Lyles C, Stambolis VA, et al. (1999) Needle-exchange attendance and health care utilization promote entry into detoxification. J Urban Health 76: 448-460.
57. Wood E, Kerr T, Marshall BDL, Li K, Zhang R, et al. (2009) Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 338: b1649.
58. Montaner JS, Lima VD, Barrios R, Yip B, Wood E, et al. (2010) Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 376: 532-539.
59. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, et al. (2010) Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375: 2092-2098.
60. Marks G, Crepaz N, Senterfitt JW, Janssen RS, (2005) Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr 39: 446-453.
61. van Kesteren NM, Hospers HJ, Kok G, (2007) Sexual risk behavior among HIV-positive men who have sex with men: a literature review. Patient Educ Couns 65: 5-20.
62. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, et al. (2003) Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362: 22-29.
63. Egger M, May M, Chêne G, Phillips AN, Ledergerber B, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360: 119-129.
64. Sorensen JL, Copeland AL, (2000) Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend 59: 17-31.
65. Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, et al. (2001) Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 15: 1707-1715.
66. Gowing L, Farrell M, Bornemann R, Sullivan LE, Ali R (2008) Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev Issue 2. Art. No.: CD004145: DOI: 10.1002/14651858.CD14004145.pub14651853.
67. Arroyo J, Hassan S, Gutierrez C, Pavon J, (2010) Re-thinking simulation: a methodological approach for the application of data mining in agent-based modelling. Comput Math Organ Th 16: 416-435.
68. Brady JE, Friedman SR, Cooper HL, Flom PL, Tempalski B, et al. (2008) Estimating the prevalence of injection drug users in the U.S. and in large U.S. metropolitan areas from 1992 to 2002. J Urban Health 85: 323-351.
69. Lieb S, Friedman SR, Zeni MB, Chitwood DD, Liberti TM, et al. (2004) An HIV prevalence-based model for estimating urban risk populations of injection drug users and men who have sex with men. J Urban Health 81: 401-415.
70. Tempalski B, Lieb S, Cleland CM, Cooper H, Brady JE, et al. (2009) HIV prevalence rates among injection drug users in 96 large US metropolitan areas, 1992-2002. J Urban Health 86: 132-154.
71. Lieb S, Fallon SJ, Friedman SR, Thompson DR, Gates GJ, et al. (2011) Statewide estimation of racial/ethnic populations of men who have sex with men in the U.S. Public Health Rep. 126: 60-72.
72. Xu F, Sternberg MR, Markowitz LE, (2010) Men who have sex with men in the United States: demographic and behavioral characteristics and prevalence of HIV and HSV-2 infection: results from National Health and Nutrition Examination Survey 2001-2006. Sex Transm Dis 37: 399-405.
73. Xu F, Sternberg MR, Markowitz LE, (2010) Women who have sex with women in the United States: prevalence, sexual behavior and prevalence of herpes simplex virus type 2 infection-results from national health and nutrition examination survey 2001-2006. Sex Transm Dis 37: 407-413.
74. Substance Abuse and Mental Health Services Administration (2010) National Prevalence Estimates for Top 20 Metropolitan Statistical Areas (MSAs). Office of Applied Studies, U.S. Department of Health and Human Service. Available: http://oas.samhsa.gov/2k5States/metro2k5PE.doc. Accessed 11 December 2011.
75. Warner LA, Kessler RC, Hughes M, Anthony JC, Nelson CB, (1995) Prevalence and correlates of drug use and dependence in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 52: 219-229.
76. Marshall BDL, Wood E, Li K, Kerr T, (2007) Elevated syringe borrowing among men who have sex with men: a prospective study. J Acquir Immune Defic Syndr 46: 248-252.
77. Young RM, Friedman SR, Case P, Asencio MW, Clatts M, (2000) Women injection drug users who have sex with women exhibit increased HIV infection and risk behaviors. J Drug Issues 30: 499-523.
78. Bell AV, Ompad D, Sherman SG, (2006) Sexual and drug risk behaviors among women who have sex with women. Am J Public Health 96: 1066-1072.
79. Ompad DC, Friedman SR, Hwahng SJ, Nandi V, Fuller CM, et al. (2011) HIV risk behaviors among young drug using women who have sex with women (WSWs) in New York City. Subst Use Misuse 46: 274-284.
80. Absalon J, Fuller CM, Ompad DC, Blaney S, Koblin B, et al. (2006) Gender differences in sexual behaviors, sexual partnerships, and HIV among drug users in New York City. AIDS Behav 10: 707-715.
81. Catania JA, Osmond D, Stall RD, Pollack L, Paul JP, et al. (2001) The continuing HIV epidemic among men who have sex with men. Am J Public Health 91: 907-914.
82. Pathela P, Hajat A, Schillinger J, Blank S, Sell R, et al. (2006) Discordance between sexual behavior and self-reported sexual identity: a population-based survey of New York City men. Ann Intern Med 145: 416-425.
83. Kral AH, Lorvick J, Ciccarone D, Wenger L, Gee L, et al. (2005) HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco. J Urban Health 82: i43-i50.
84. Knight KR, Shade SB, Purcell DW, Rose CD, Metsch LR, et al. (2007) Sexual transmission risk behavior reported among behaviorally bisexual HIV-positive injection drug-using men. J Acquir Immune Defic Syndr 46: S80-S87.
85. Friedman SR, Bolyard M, Mateu-Gelabert P, Goltzman P, Pawlowicz MP, et al. (2007) Some data-driven reflections on priorities in AIDS network research. AIDS Behav 11: 641-651.
86. Hamilton DT, Handcock MS, Morris M, (2008) Degree distributions in sexual networks: a framework for evaluating evidence. Sex Transm Dis 35: 30-40.
87. Newman ME, Watts DJ, Strogatz SH, (2002) Random graph models of social networks. Proc Natl Acad Sci U S A 99: 2566-2572.
88. Latkin CA, Forman V, Knowlton A, Sherman S, (2003) Norms, social networks, and HIV-related risk behaviors among urban disadvantaged drug users. Soc Sci Med 56: 465-476.
89. Kottiri BJ, Friedman SR, Neaigus A, Curtis R, Des Jarlais DC, (2002) Risk networks and racial/ethnic differences in the prevalence of HIV infection among injection drug users. J Acquir Immune Defic Syndr 30: 95-104.
90. Jose B (1996) Racial/ethnic variations in the prevalence of human immunodeficiency virus type 1 infection among injecting drug users: Social and behavioral risk factors. New York, NY: ETD Collection for Fordham University.
91. Molitor F, Truax SR, Ruiz JD, Sun RK, (1998) Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. West J Med 168: 93-97.
92. Khan MR, Bolyard M, Sandoval M, Mateu-Gelabert P, Krauss B, et al. (2009) Social and behavioral correlates of sexually transmitted infection- and HIV-discordant sexual partnerships in Bushwick, Brooklyn, New York. J Acquir Immune Defic Syndr 51: 470-485.
93. Kuo I, Greenberg AE, Magnus M, Phillips G, 2nd, Rawls A, et al (2011) High prevalence of substance use among heterosexuals living in communities with high rates of AIDS and poverty in Washington, DC. Drug Alcohol Depend 117: 139-144.
94. Howard DL, Latkin CA, (2006) A bridge over troubled waters: factors associated with non-injection drug users having injection drug-using sex partners. J Acquir Immune Defic Syndr 42: 325-330.
95. Jenness SM, Neaigus A, Hagan H, Murrill CS, Wendel T, (2010) Heterosexual HIV and sexual partnerships between injection drug users and noninjection drug users. AIDS Patient Care STDS 24: 175-181.
96. Sherman SG, Latkin CA, (2001) Intimate relationship characteristics associated with condom use among drug users and their sex partners: a multilevel analysis. Drug Alcohol Depend 64: 97-104.
97. Sullivan PS, Salazar L, Buchbinder S, Sanchez TH, (2009) Estimating the proportion of HIV transmissions from main sex partners among men who have sex with men in five US cities. AIDS 23: 1153-1162.
98. Adimora AA, Schoenbach VJ, Doherty IA, (2007) Concurrent sexual partnerships among men in the United States. Am J Public Health 97: 2230-2237.
99. Adimora AA, Schoenbach VJ, Bonas DM, Martinson FE, Donaldson KH, et al. (2002) Concurrent sexual partnerships among women in the United States. Epidemiology 13: 320-327.
100. Sell RL, Wells JA, Wypij D, (1995) The prevalence of homosexual behavior and attraction in the United States, the United Kingdom and France: results of national population-based samples. Arch Sex Behav 24: 235-248.
101. Leigh BC, Temple MT, Trocki KF, (1993) The sexual behavior of US adults: results from a national survey. Am J Public Health 83: 1400-1408.
102. Maslow CB, Friedman SR, Perlis TE, Rockwell R, Des Jarlais DC, (2002) Changes in HIV seroprevalence and related behaviors among male injection drug users who do and do not have sex with men: New York City, 1990-1999. Am J Public Health 92: 382-384.
103. Arasteh K, Des Jarlais DC, Perlis TE, (2008) Alcohol and HIV sexual risk behaviors among injection drug users. Drug Alcohol Depend 95: 54-61.
104. Kral AH, Lorvick J, Bluthenthal RN, Watters JK, (1997) HIV risk profile of drug-using women who have sex with women in 19 United States cities. J Acquir Immune Defic Syndr Hum Retrovirol 16: 211-217.
105. Colfax G, Coates TJ, Husnik MJ, Huang Y, Buchbinder S, et al. (2005) Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of san francisco men who have sex with men. J Urban Health 82: i62-70.
106. Des Jarlais DC, Hagan H, Arasteh K, McKnight C, Perlman D, et al. (2007) Herpes simplex virus-2 and HIV among noninjecting drug users in New York city. Sex Transm Dis 34: 923-927.
107. Des Jarlais DC, Arasteh K, McKnight C, Perlman D, Hagan H, et al. (2010) Gender and age patterns in HSV-2 and HIV infection among non-injecting drug users in New York City. Sex Transm Dis 37: 637-643.
108. Lemp GF, Jones M, Kellogg TA, Nieri GN, Anderson L, et al. (1995) HIV seroprevalence and risk behaviors among lesbians and bisexual women in San Francisco and Berkeley, California. Am J Public Health 85: 1549-1552.
109. Mercer CH, Bailey JV, Johnson AM, Erens B, Wellings K, et al. (2007) Women who report having sex with women: British national probability data on prevalence, sexual behaviors, and health outcomes. Am J Public Health 97: 1126-1133.
110. Ekstrand ML, Stall RD, Paul JP, Osmond DH, Coates TJ, (1999) Gay men report high rates of unprotected anal sex with partners of unknown or discordant HIV status. AIDS 13: 1525-1533.
111. Marshall BDL, Wood E, Zhang R, Tyndall MW, Montaner JS, et al. (2009) Condom use among injection drug users accessing a supervised injecting facility. Sex Transm Infect 85: 121-126.
112. Vanichseni S, Des Jarlais DC, Choopanya K, Friedmann P, Wenston J, et al. (1993) Condom use with primary partners among injecting drug users in Bangkok, Thailand and New York City, United States. AIDS 7: 887-891.
113. Friedman SR, Jose B, Neaigus A, Goldstein M, Curtis R, et al. (1994) Consistent condom use in relationships between seropositive injecting drug users and sex partners who do not inject drugs. AIDS 8: 357-361.
114. Gorbach PM, Weiss RE, Jeffries R, Javanbakht M, Drumright LN, et al. (2011) Behaviors of recently HIV-infected men who have sex with men in the year postdiagnosis: effects of drug use and partner types. J Acquir Immune Defic Syndr 56: 176-182.
115. Ostrow DE, Fox KJ, Chmiel JS, Silvestre A, Visscher BR, et al. (2002) Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men. AIDS 16: 775-780.
116. Des Jarlais C, Perlis T, Friedman SR, Chapman T, Kwok J, et al. (2000) Behavioral risk reduction in a declining HIV epidemic: injection drug users in New York City, 1990-1997. Am J Public Health 90: 1112-1116.
117. Tempalski B, Cleland CM, Pouget ER, Chatterjee S, Friedman SR, (2010) Persistence of low drug treatment coverage for injection drug users in large US metropolitan areas. Subst Abuse Treat Prev Policy 5: 23.
118. Booth RE, Crowley TJ, Zhang Y, (1996) Substance abuse treatment entry, retention and effectiveness: out-of-treatment opiate injection drug users. Drug Alcohol Depend 42: 11-20.
119. Brooner R, Kidorf M, King V, Beilenson P, Svikis D, et al. (1998) Drug abuse treatment success among needle exchange participants. Public Health Rep 113: 129-139.
120. Zule WA, Desmond DP, (2000) Factors predicting entry of injecting drug users into substance abuse treatment. Am J Drug Alcohol Abuse 26: 247-261.
121. Watkins KE, Metzger D, Woody G, McLellan AT, (1992) High-risk sexual behaviors of intravenous drug users in- and out-of-treatment: implications for the spread of HIV infection. Am J Drug Alcohol Abuse 18: 389-398.
122. Watters JK, Estilo MJ, Clark GL, Lorvick J, (1994) Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA 271: 115-120.
123. Kaplan EH, Heimer R, (1992) A model-based estimate of HIV infectivity via needle sharing. J Acquir Immune Defic Syndr 5: 1116-1118.
124. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, et al. (1999) Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 150: 306-311.
125. Royce RA, Sena A, Cates W Jr, Cohen MS, (1997) Sexual transmission of HIV. N Engl J Med 336: 1072-1078.
126. Baggaley RF, White RG, Boily MC, (2010) HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol 39: 1048-1063.
127. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, et al. (2001) Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357: 1149-1153.
128. Raboud JM, Boily MC, Rajeswaran J, O'Shaughnessy MV, Schechter MT, (2003) The impact of needle-exchange programs on the spread of HIV among injection drug users: a simulation study. J Urban Health 80: 302-320.
129. Downs AM, De Vincenzi I, (1996) Probability of heterosexual transmission of HIV: relationship to the number of unprotected sexual contacts. European Study Group in Heterosexual Transmission of HIV. J Acquir Immune Defic Syndr Hum Retrovirol 11: 388-395.
130. Hughes JP, Baeten JM, Lingappa JR, Magaret AS, Wald A, et al. (2012) Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis 205: 358-365.
131. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, et al. (2005) Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 191: 1403-1409.
132. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, et al. (2000) Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 14: 357-366.
133. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, et al. (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. New Eng J Med 342: 921-929.
134. Attia S, Egger M, Muller M, Zwahlen M, Low N, (2009) Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 23: 1397-1404.
135. Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, et al. (2003) Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ 169: 656-661.
136. Ortego C, Huedo-Medina TB, Llorca J, Sevilla L, Santos P, et al. (2011) Adherence to highly active antiretroviral therapy (HAART): A meta-analysis. AIDS Behav 15: 1381-1396.
137. Lucas GM, Chaisson RE, Moore RD, (1999) Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 131: 81-87.
138. Malta M, Magnanini MM, Strathdee SA, Bastos FI, (2010) Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav 14: 731-747.
139. Kerr T, Marshall A, Walsh J, Palepu A, Tyndall M, et al. (2005) Determinants of HAART discontinuation among injection drug users. AIDS Care 17: 539-549.
140. Zaccarelli M, Barracchini A, De Longis P, Perno CF, Soldani F, et al. (2002) Factors related to virologic failure among HIV-positive injecting drug users treated with combination antiretroviral therapy including two nucleoside reverse transcriptase inhibitors and nevirapine. AIDS Patient Care STDS 16: 67-73.
141. Morris JD, Golub ET, Mehta SH, Jacobson LP, Gange SJ, (2007) Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts. AIDS Res Ther 4: 12.
142. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, et al. (2000) Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 14: 499-507.
143. Moss AR, Bacchetti P, (1989) Natural history of HIV infection. AIDS 3: 55-61.
144. CASCADE Collaboration, (2003) Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 362: 1267-1274.
145. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, et al. (2001) Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15: 1181-1183.
146. Shah NG, Galai N, Celentano DD, Vlahov D, Strathdee SA, (2006) Longitudinal predictors of injection cessation and subsequent relapse among a cohort of injection drug users in Baltimore, MD, 1988-2000. Drug Alcohol Depend 83: 147-156.
147. Windrum P, Fagiolo G, Moneta A, (2007) Empirical validation of agent-based models: alternatives and prospects. JASSS- J Artif Soc S 10: 8.
148. Nagoski E, Janssen E, Lohrmann D, Nichols E (2011) Risk, individual differences, and environment: An agent-based modeling approach to sexual risk-taking. Arch Sex Behav. DOI: 10.1007/s10508-011-9867-5.
149. Yang Y, Diez Roux AV, Auchincloss AH, Rodriguez DA, Brown DG, (2011) A spatial agent-based model for the simulation of adults' daily walking within a city. Am J Prev Med 40: 353-361.
150. Potterat JJ, Rothenberg RB, Muth SQ, (1999) Network structural dynamics and infectious disease propagation. Int J STD AIDS 10: 182-185.
151. Potterat JJ, Phillips-Plummer L, Muth SQ, Rothenberg RB, Woodhouse DE, et al. (2002) Risk network structure in the early epidemic phase of HIV transmission in Colorado Springs. Sex Transm Infect 78: i159-i163.
152. Centers for Disease Control and Prevention (2010) Prevalence and awareness of HIV infection among men who have sex with men -- 21 cities, United States, 2008. MMWR Morb Mortal Wkly Rep 59: 1201-1207.
153. Wolitski RJ, Valdiserri RO, Denning PH, Levine WC, (2001) Are we headed for a resurgence of the HIV epidemic among men who have sex with men? Am J Public Health 91: 883-888.
154. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, et al. (2010) HIV and risk environment for injecting drug users: the past, present, and future. Lancet 376: 268-284.
155. Morris M, Kurth AE, Hamilton DT, Moody J, Wakefield S, (2009) Concurrent partnerships and HIV prevalence disparities by race: linking science and public health practice. Am J Public Health 99: 1023-1031.
156. Goodreau SM, Cassels S, Kasprzyk D, Montano DE, Greek A, et al. (2012) Concurrent partnerships, acute infection and HIV epidemic dynamics among young adults in Zimbabwe. AIDS Behav 16: 312-322.
157. Cohen J, (2011) Halting HIV/AIDS Epidemics. Science 334: 1338-1340.
158. Auchincloss AH, Riolo RL, Brown DG, Cook J, Diez Roux AV, (2011) An agent-based model of income inequalities in diet in the context of residential segregation. Am J Prev Med 40: 303-311.
159. Jones GT, (2007) Agent-based modeling: use with necessary caution. Am J Public Health 97: 780-781.
160. Grimm V, Berger U, Bastiansen F, Eliassen S, Ginot V, et al. (2006) A standard protocol for describing individual-based and agent-based models. Ecol Model 198: 115-126.
161. Cioffi-Revilla C, (2002) Invariance and universality in social agent-based simulations. Proc Natl Acad Sci USA 99: 7314-7316.
162. Lloyd JJ, Strathdee SA, Pu M, Havens JR, Cornelius LJ, et al. (2008) The impact of opiate agonist maintenance therapy on drug use within social networks of injecting drug users. Am J Addict 17: 414-421.
163. Miller M, Neaigus A, (2002) Sex partner support, drug use and sex risk among HIV-negative non-injecting heroin users. AIDS Care 14: 801-813.
164. Copeland L, Budd J, Robertson JR, Elton RA, (2004) Changing patterns in causes of death in a cohort of injecting drug users, 1980-2001. Arch Intern Med 164: 1214-1220.
165. van Haastrecht HJ, van Ameijden EJ, van den Hoek JA, Mientjes GH, Bax JS, et al. (1996) Predictors of mortality in the Amsterdam cohort of human immunodeficiency virus (HIV)-positive and HIV-negative drug users. Am J Epidemiol 143: 380-391.
166. Zaccarelli M, Gattari P, Rezza G, Conti S, Spizzichino L, et al. (1994) Impact of HIV infection on non-AIDS mortality among Italian injecting drug users. AIDS 8: 345-350.
167. Wood E, Hogg RS, Lima VD, Kerr T, Yip B, et al. (2008) Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA 300: 550-554.
168. Brown LS Jr, Siddiqui NS, Chu AF, (1996) Natural history of HIV-1 infection and predictors of survival in a cohort of HIV-1 seropositive injecting drug users. J Natl Med Assoc 88: 37-42.
169. Vlahov D, Galai N, Safaeian M, Galea S, Kirk GD, et al. (2005) Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol 161: 999-1012.
170. Metzger DS, Woody GE, McLellan AT, O'Brien CP, Druley P, et al. (1993) Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 6: 1049-1056.
171. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, et al. (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337: 734-739.
172. Uhlmann S, Milloy MJ, Kerr T, Zhang R, Guillemi S, et al. (2010) Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction 105: 907-913.
173. Kapadia F, Cook JA, Cohen MH, Sohler N, Kovacs A, et al. (2005) The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use. Addiction 100: 990-1002.
174. Anderson JE, Carey JW, Taveras S, (2000) HIV testing among the general US population and persons at increased risk: information from national surveys, 1987-1996. Am J Public Health 90: 1089-1095.
175. McGowan CC, Weinstein DD, Samenow CP, Stinnette SE, Barkanic G, et al. (2011) Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. PLoS ONE 6: e18462.
176. New York State Department of Health (1994) HIV infection in New York State.
177. Mortality patterns-United States, 1992. MMWR Morb Mortal Wkly Rep 43: 916-920.
178. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, et al. (2002) Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 16: 1663-1671.
179. Cole SR, Hernan MA, Robins JM, Anastos K, Chmiel J, et al. (2003) Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 158: 687-694.